Study summary
Adding chemotherapy to osimertinib helped people live about 10 months longer
47.5months median survival, vs 37.6 with osimertinib alone
What was tested
Osimertinib plus pemetrexed and platinum chemotherapy against osimertinib alone, as first treatment for advanced lung cancer with a common EGFR mutation (exon 19 deletion or L858R).
What they found
- Median overall survival was 47.5 months with the combination vs 37.6 months with osimertinib alone.
- Severe side effects were more common with the combination (70% vs 34%), mostly from chemotherapy and reversible.
What it means
Gives people a choice between a stronger start with more side effects, or osimertinib pills alone.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.